AMGN

#70
Amgen Inc
348.22 USD
-0.78%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
348.01
348.22
Rango anual
261.43
391.29
Cambio diario
-0.78%
Variación mensual
-5.73%
Variación en los últimos 6 meses
+16.65%
Cambio anual
+18.14%
Cierres anteriores
350.95
Abrir
348.01
Bid
Ask
Mínimo
348.01
High
348.22
Volumen
360
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 187.71 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
23
Relación precio/flujo de caja
4.83
Dividendos por acción
2.52
Rendimiento por dividendo, %
2.95

Amgen Inc

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

Noticias